Las antiguas drogas antitrombóticas, ¿serán enviadas al museo?
DOI:
https://doi.org/10.24265/horizmed.2022.v22n2.00Resumo
El desarrollo y prescripción de drogas que alteran el equilibrio del sistema de hemostasia ha constituido un gran avance en el tratamiento y la prevención de eventos tromboembólicos, que ha logrado disminuir de manera drástica la morbimortalidad asociada a ellos. El descubrimiento de la heparina y de los cumarínicos, así como la descripción de sus actividades trombóticas, abrió un nuevo panorama terapéutico.
Downloads
Referências
McLean J. The thromboplastic action of cephalin. Am J Physiol. 1916.
McLean J. The discovery of heparin. Circulation. 1959; 19(1): 75-8.
Campbell HA, Smith WK, Roberts WL, Link KP. Studies on the hemorrhagic sweet clover disease: II. The bioassay of hemorrhagic concentrates by following the prothrombin level in the plasma of rabbit blood. J Biol Chem. 1941; 138(1): 1-20.
Gibson P. Salicylic acid for coronary thrombosis? Lancet. 1948; 1(6512): 965.
Gibson P. Aspirin in the treatment of vascular diseases. Lancet. 1949; 2(6591): 1172-4.
Salzman EW, Deykin D, Shapiro RM, Rosenberg R. Management of heparin therapy: controlled prospective trial. N Engl J Med. 1975; 292(20): 1046-50.
Kakkar VV, Corrigan T, Spindler J, Fossard DP, Flute PT, Crelling RQ, et al. Efficacy of low doses of heparin in prevention of deep-vein thrombosis after major surgery: a double-blind, randomised trial. Lancet. 1972; 2(7768): 101-6.
Kakkar VV, Corrigan TP, Fossard DP, Sutherland I, Thirwell J. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. Lancet. 1975; 2(7924): 45-51.
Columbus Investigators, Buller HR, Gent M, Gallus AS, Ginsberg J, Prins MH, et al. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 1997; 337(10): 657-62.
4th American College of Chest Physicians Consensus Conference on Antithrombotic Therapy. Tucson, Arizona, April 1995. Proceedings. Chest. 1995; 108(Suppl. 4): 312-34.
Baumann MH, Strange C, Heffner JE, Light R, Kirby TJ, Klein J, et al. Management of spontaneous pneumothorax: an American College of Chest Physicians Delphi consensus statement. Chest. 2001; 119(2): 590-602.
Kakkar VV. Efficacy and safety of clivarin and other LMWHs in general surgery: a meta-analysis. Blood Coagul Fibrinolysis. 1993; 4(Suppl. 1): 23-7.
Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002; 162(16): 1833-40.
Wright IS. Experiences with dicumarol (3,3'-methylene-bis[4-hydroxycoumarin]) in the treatment of coronary thrombosis with myocardial infarction; preliminary report. Am Heart J. 1946; 32(1): 20-31.
Bauer KA. Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. J Thromb Haemost. 2011; 9(Suppl. 1): 12-9.
O’Connell C, Escalante CP, Goldhaber SZ, McBane R, Connors JM, Raskob GE. Treatment of cancer-associated venous thromboembolism with low-molecular-weight heparin or direct oral anticoagulants: patient selection, controversies, and caveats. Oncologist. 2021; 26(1): e8-16.
Ruiz Mori E. Antiagregantes plaquetarios. Rev Peru Cardiol. 2006; XXXII(1): 29-38.
Lugo LM, Herrero JL. Tratamiento antitrombótico doble frente a triple. Rev Esp Cardiol. 2019; 18(Supl. A): 27-33.
Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing G-J, et al. Antithrombotic therapy for VTE disease. Second update of the CHEST guideline and expert panel report. Chest. 2021; 160(6): e545-608.
Greer DM. Aspirin and antiplatelet agent resistance: implications for prevention of secondary stroke. CNS Drugs. 2010; 24(12): 1027-40.
Kraaijpoel N, Carrier M. How I treat cancer-associated venous thromboembolism. Blood. 2019; 133(4): 291-8.
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2022 Horizonte Médico (Lima)
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Os resultados de pesquisa da revista Horizonte Médico (Lima) (Horiz. Med.) são publicados sem custo e estão disponíveis gratuitamente para download sob o modelo de acesso aberto, com o objetivo de disseminar trabalhos e experiências desenvolvidos nas áreas biomédica e de saúde pública, tanto nacional quanto internacionalmente, e promover a pesquisa nos diferentes campos da medicina humana. Todos os manuscritos aceitos e publicados na revista são distribuídos gratuitamente sob os termos de uma licença Creative Commons - Atribuição 4.0 Internacional (CC BY 4.0).
